Literature DB >> 9836378

Biological insights from clinical trials with anti-TNF therapy.

M Feldmann1, P Charles, P Taylor, R N Maini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9836378     DOI： 10.1007/bf00832008

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  54 in total

1.  A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells.

Authors:  R A Black; C T Rauch; C J Kozlosky; J J Peschon; J L Slack; M F Wolfson; B J Castner; K L Stocking; P Reddy; S Srinivasan; N Nelson; N Boiani; K A Schooley; M Gerhart; R Davis; J N Fitzner; R S Johnson; R J Paxton; C J March; D P Cerretti
Journal:  Nature       Date:  1997-02-20       Impact factor: 49.962

Review 2.  Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis.

Authors:  M Feldmann; M J Elliott; J N Woody; R N Maini
Journal:  Adv Immunol       Date:  1997       Impact factor: 3.543

3.  Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis.

Authors:  E M Paleolog; M Hunt; M J Elliott; M Feldmann; R N Maini; J N Woody
Journal:  Arthritis Rheum       Date:  1996-07

Review 4.  Interleukin 6 and its receptor: ten years later.

Authors:  T Hirano
Journal:  Int Rev Immunol       Date:  1998       Impact factor: 5.311

5.  Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4.

Authors:  R O Williams; J Ghrayeb; M Feldmann; R N Maini
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

6.  Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases.

Authors:  A P Cope; D Aderka; M Doherty; H Engelmann; D Gibbons; A C Jones; F M Brennan; R N Maini; D Wallach; M Feldmann
Journal:  Arthritis Rheum       Date:  1992-10

7.  Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing.

Authors:  K M Mohler; P R Sleath; J N Fitzner; D P Cerretti; M Alderson; S S Kerwar; D S Torrance; C Otten-Evans; T Greenstreet; K Weerawarna
Journal:  Nature       Date:  1994-07-21       Impact factor: 49.962

8.  The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis.

Authors:  N Sommer; P A Löschmann; G H Northoff; M Weller; A Steinbrecher; J P Steinbach; R Lichtenfels; R Meyermann; A Riethmüller; A Fontana
Journal:  Nat Med       Date:  1995-03       Impact factor: 53.440

9.  Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice.

Authors:  S Georgopoulos; D Plows; G Kollias
Journal:  J Inflamm       Date:  1996

10.  Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice.

Authors:  P H Wooley; J Dutcher; M B Widmer; S Gillis
Journal:  J Immunol       Date:  1993-12-01       Impact factor: 5.422
View more
  12 in total

Review 1.  Unlinking tumor necrosis factor biology from the major histocompatibility complex: lessons from human genetics and animal models.

Authors:  S R Ruuls; J D Sedgwick
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

Review 2.  Science, medicine, and the future: Tolerance and autoimmunity.

Authors:  I R Mackay
Journal:  BMJ       Date:  2000-07-08

Review 3.  Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection.

Authors:  Richard Long; Michael Gardam
Journal:  CMAJ       Date:  2003-04-29       Impact factor: 8.262

Review 4.  [Do B cells play an important role in the pathogenesis of rheumatoid arthritis?].

Authors:  C Berek
Journal:  Z Rheumatol       Date:  2005-09       Impact factor: 1.372

5.  A proinflammatory role for IL-18 in rheumatoid arthritis.

Authors:  J A Gracie; R J Forsey; W L Chan; A Gilmour; B P Leung; M R Greer; K Kennedy; R Carter; X Q Wei; D Xu; M Field; A Foulis; F Y Liew; I B McInnes
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

6.  Increased FcgammaRII expression and aberrant tumour necrosis factor alpha production by mature dendritic cells from patients with active rheumatoid arthritis.

Authors:  T R D J Radstake; A B Blom; A W Slöetjes; E O F van Gorselen; G J Pesman; L Engelen; R Torensma; W B van den Berg; C G Figdor; P L E M van Lent; G J Adema; P Barrera
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

Review 7.  Update on synovitis.

Authors:  Z Szekanecz; A E Koch
Journal:  Curr Rheumatol Rep       Date:  2001-02       Impact factor: 4.686

Review 8.  Etanercept biosimilars.

Authors:  Valderilio F Azevedo; Nathalia Galli; Alais Kleinfelder; Julia D'Ippolito; Paulo C M Urbano
Journal:  Rheumatol Int       Date:  2014-07-01       Impact factor: 2.631

9.  Rheumatoid arthritis synovium contains plasmacytoid dendritic cells.

Authors:  Lois L Cavanagh; Amanda Boyce; Louise Smith; Jagadish Padmanabha; Luis Filgueira; Peter Pietschmann; Ranjeny Thomas
Journal:  Arthritis Res Ther       Date:  2005-01-11       Impact factor: 5.156

Review 10.  Biologics in dermatology: an integrated review.

Authors:  Virendra N Sehgal; Deepika Pandhi; Ananta Khurana
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.